NZ266314A - Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions - Google Patents

Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions

Info

Publication number
NZ266314A
NZ266314A NZ266314A NZ26631494A NZ266314A NZ 266314 A NZ266314 A NZ 266314A NZ 266314 A NZ266314 A NZ 266314A NZ 26631494 A NZ26631494 A NZ 26631494A NZ 266314 A NZ266314 A NZ 266314A
Authority
NZ
New Zealand
Prior art keywords
various
indane
hetero
aryl
carboxylic acid
Prior art date
Application number
NZ266314A
Other languages
English (en)
Inventor
Russell Donovan Cousins
John Duncan Elliott
Maria Amparo Lago
Jack Dale Leber
Catherine Elizabeth Peishoff
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NZ266314A publication Critical patent/NZ266314A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30Unsaturated compounds
    • C07C62/34Unsaturated compounds containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ266314A 1993-04-27 1994-04-26 Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions NZ266314A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6681893A 1993-04-27 1993-04-27
PCT/US1994/004603 WO1994025013A1 (en) 1993-04-27 1994-04-26 Endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
NZ266314A true NZ266314A (en) 1998-10-28

Family

ID=22071916

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ266314A NZ266314A (en) 1993-04-27 1994-04-26 Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions

Country Status (28)

Country Link
EP (1) EP0699069B9 (enExample)
JP (1) JP3346571B2 (enExample)
KR (1) KR100331667B1 (enExample)
CN (1) CN1129428C (enExample)
AP (1) AP573A (enExample)
AT (1) ATE213156T1 (enExample)
AU (1) AU682038B2 (enExample)
BR (1) BR9406572A (enExample)
CA (1) CA2160914A1 (enExample)
CZ (1) CZ291189B6 (enExample)
DE (1) DE69429861T2 (enExample)
DK (1) DK0699069T3 (enExample)
DZ (1) DZ1773A1 (enExample)
ES (1) ES2172535T3 (enExample)
FI (1) FI955103A7 (enExample)
HU (2) HU9503067D0 (enExample)
IL (1) IL109443A0 (enExample)
MA (1) MA23172A1 (enExample)
NO (1) NO313754B1 (enExample)
NZ (1) NZ266314A (enExample)
PL (1) PL175392B1 (enExample)
PT (1) PT699069E (enExample)
RU (1) RU2130920C1 (enExample)
SG (1) SG49667A1 (enExample)
SI (1) SI9400195B (enExample)
SK (1) SK130595A3 (enExample)
TW (1) TW330204B (enExample)
WO (1) WO1994025013A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075037A (en) * 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
JPH10501812A (ja) * 1994-06-20 1998-02-17 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗薬
WO1996020193A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation Compounds and methods
AU7677496A (en) * 1995-11-08 1997-05-29 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
ZA969363B (en) * 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
IL126175A (en) 1996-04-04 2003-05-29 Banyu Pharma Co Ltd Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
AU3867997A (en) 1996-08-27 1998-03-19 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
JP2002511442A (ja) * 1998-04-09 2002-04-16 メルク エンド カムパニー インコーポレーテッド ホスフェート介在の環化
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
NZ586285A (en) 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
US7423176B2 (en) 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
WO2006066748A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof as 5-ht antagonists
US20100040666A1 (en) * 2005-06-24 2010-02-18 Hiroshi Azuma Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent
JP4989648B2 (ja) 2005-08-03 2012-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗癌剤として有用なイルジン類似体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
FI942059A7 (fi) * 1991-11-05 1994-07-04 Smithkline Beecham Corp Endoteliinireseptoreiden antagonisteja

Also Published As

Publication number Publication date
DZ1773A1 (fr) 2002-02-17
PL175392B1 (pl) 1998-12-31
AP573A (en) 1997-01-30
FI955103A0 (fi) 1995-10-26
WO1994025013A1 (en) 1994-11-10
NO954291D0 (no) 1995-10-26
AU682038B2 (en) 1997-09-18
CZ283595A3 (en) 1996-03-13
SK130595A3 (en) 1996-06-05
DE69429861D1 (de) 2002-03-21
DK0699069T3 (da) 2002-05-27
HU9503067D0 (en) 1995-12-28
CN1129428C (zh) 2003-12-03
RU2130920C1 (ru) 1999-05-27
CN1124923A (zh) 1996-06-19
PT699069E (pt) 2002-07-31
SG49667A1 (en) 1998-06-15
EP0699069B9 (en) 2003-10-22
NO954291L (no) 1995-12-21
EP0699069B1 (en) 2002-02-13
NO313754B1 (no) 2002-11-25
FI955103L (fi) 1995-10-26
SI9400195A (en) 1994-12-31
HU9501931D0 (en) 1995-09-28
MA23172A1 (fr) 1994-12-31
FI955103A7 (fi) 1995-10-26
EP0699069A1 (en) 1996-03-06
TW330204B (en) 1998-04-21
CZ291189B6 (cs) 2003-01-15
DE69429861T2 (de) 2002-09-19
IL109443A0 (en) 1994-07-31
HK1012252A1 (en) 1999-07-30
JP3346571B2 (ja) 2002-11-18
ATE213156T1 (de) 2002-02-15
CA2160914A1 (en) 1994-11-10
HUT73763A (en) 1996-09-30
PL311272A1 (en) 1996-02-05
JPH08510211A (ja) 1996-10-29
KR100331667B1 (ko) 2002-11-08
AP9400636A0 (en) 1994-04-30
EP0699069A4 (enExample) 1996-04-03
ES2172535T3 (es) 2002-10-01
BR9406572A (pt) 1996-01-30
SI9400195B (sl) 2003-10-31
AU6775094A (en) 1994-11-21

Similar Documents

Publication Publication Date Title
NZ266314A (en) Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions
GB2230185B (en) Sustained release pharmaceutical compositions
HUT63407A (en) Process for producing substituted indole, indene, piranoindole and tetrahydrocarbazole alkanoic acid derivatives and pharmaceutical compositions comprising such compounds as active ingredient
IL111627A0 (en) Substituted phenylpyrimidine compounds, their preparation and pharmaceutical compositions containing them
IL108372A0 (en) 2,6-Diaminopurine derivatives, their preparation and pharmaceutical compositions containing them
IL100899A0 (en) Beta-amino-alpha-hydroxycarboxylic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
HUP9901296A3 (en) Substituted piperidine derivatives as nmda receptor antagonists and pharmaceutical compositions containing them
IL102261A0 (en) 7-isoindolinyl-quinolone-and-naphthyridonecarboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
NZ235726A (en) Substituted pyrimidine derivatives; their preparation and pharmaceutical compositions
IL103126A (en) 5-amino-4-hydroxyhexanoic acid derivatives, process for their preparation and pharmaceutical compositions containing them
NZ237191A (en) 2-((substituted amide) substituted heterocyclylthio) carbpen-2-em derivatives and pharmaceutical compositions
IL101771A0 (en) Carboxylic acid derivatives,their manufacture and pharmaceutical compositions containing them
IL103437A0 (en) Cyclohexaneacetic acid derivatives,their preparation and pharmaceutical compositions containing them
NZ231353A (en) Pharmaceutical compositions comprising 3,5-dihydroxy-7-(1-acyloxyhexahydronaphth-8-yl)-heptanoic acid and lactone derivatives
IL103293A0 (en) Substituted imidazolyl-propenoic acid derivatives,their preparation and pharmaceutical compositions containing them
IL103058A0 (en) Bicyclic carboxylic acid derivatives,their manufacture and pharmaceutical compositions containing them
HUT56359A (en) Process for producing leukotriene antagonist compounds and pharmaceutical compositions comprising same as active ingredient
IL98223A0 (en) Pharmaceutical compositions containing fluorene derivatives,some such novel compounds and their preparation
IL110480A0 (en) Methylguanidine derivatives, their preparation and pharmaceutical compositions containing them
ZA904925B (en) Sustained release pharmaceutical compositions
HU9303113D0 (en) Pharmaceutical compositions containing 1,2-dithiol-3-thione-derivatives
IL87019A0 (en) Substituted alkene carboxylic acid amides and derivatives,their manufacture and pharmaceutical compositions containing them
IL102362A0 (en) 4-amino-3-hydroxycarboxylic acid derivatives,their production and pharmaceutical compositions containing them
IL103291A0 (en) Imidazolyl-propenoic acid derivatives,their preparation and pharmaceutical compositions containing them
IL102264A0 (en) Dicarboxylic acid derivatives,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired